NEW YORK — In a landmark advancement in oncology, researchers at Rockefeller University have unveiled a sophisticated new methodology to decode how cancer cells rewire their internal metabolism to manipulate protein function, opening the door to novel therapeutic targets for notoriously aggressive malignancies like pancreatic cancer.

The collaborative breakthrough, led by Ekaterina V. Vinogradova, head of the Laboratory of Chemical Immunology and Proteomics, and Kivanç Birsoy, head of the Laboratory of Metabolic Regulation and Genetics, bridges the gap between cellular metabolism and proteomics. As detailed in a report published by Medical Xpress on August 3, 2026, the dual-laboratory effort utilizes cutting-edge chemical proteomics and mass spectrometry to observe, in real time, how shifting metabolic landscapes alter the chemical reactivity of thousands of proteins simultaneously.

"We are interested in understanding how metabolism regulates protein function during tumor growth and metastasis. If we can identify proteins that respond to specific metabolic changes, we can begin to understand their biological importance and determine whether they represent new therapeutic opportunities." — Kivanç Birsoy, Joseph L. Goldstein Professor at Rockefeller University

Unlike traditional methods that merely measure whether a protein is present, Vinogradova's innovative platforms evaluate the reactivity of chemically sensitive amino acids. This provides a direct, functional readout of changes driven by protein oxidation, structural conformational rearrangements, and altered protein interactomes. The teams are now constructing a comprehensive atlas detailing exactly how individual metabolites influence cysteine reactivity across the entire cancer cell proteome.

A critical focal point of this research is the endoplasmic reticulum (ER), a vital metabolic hub where fats and proteins are synthesized and folded. In their initial findings, the Rockefeller duo discovered that a specific protein, SLC33A1, acts as a crucial guardian of redox balance within the ER by exporting oxidized glutathione when its levels become toxic. In cancers burdened with mutations that cause redox metabolites to accumulate, artificially boosting SLC33A1 activity could restore cellular equilibrium.

This discovery carries profound implications for pancreatic cancer, a disease notoriously resistant to standard interventions. Birsoy notes that while recent drugs like daraxonrasib have extended patient lifespans by roughly six months, the baseline survival metrics remain grim. Because pancreatic cancer cells hoard massive quantities of antioxidants such as glutathione to shield themselves from oxidative stress, targeting the SLC33A1 export mechanism could effectively strip the tumor of its metabolic armor, presenting a highly promising, unprecedented drug target.

The Rockefeller University continues to spotlight the vital intersection of metabolism and oncology, highlighting the ongoing work of its leading scientists in understanding cancer cell vulnerabilities:

As the scientific community scrambles to outmaneuver tumors that evolve to survive our most potent chemotherapies, this metabolic mapping offers a new cartography of cancer's inner workings. By illuminating the exact biochemical safe havens tumors construct for themselves, researchers like Vinogradova and Birsoy are not merely observing the disease; they are drafting the blueprints to dismantle it.